Vildagliptin (galvus®) and fixed combination vildagliptine-metformin (eucreas®) in the treatment of type 2 diabetes;Le médicament du mois vildagliptine (galvus®) et combinaison fixe vildagliptine-metformine (eucreas®) dans le traitement du diabète de type 2

Revue Medicale de Liege

Volumn 64, Issue 3, 2009, Pages 161-167

  Scheen, A J ^a,b   Paquqt, N ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

1 Incretin; 4 Inhibitor; Dipeptidylpeptidase; Glucagon; Like peptide; Metformin; Type 2 diabetes; Vildagliptin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV; EUCRAS; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; METFORMIN; METFORMIN PLUS VILDAGLIPTIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; VILDAGLIPTIN;

BELGIUM; BLOOD GLUCOSE MONITORING; DIABETIC PATIENT; DIARRHEA; DIET THERAPY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPEPSIA; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; INTESTINE CELL; KIDNEY FAILURE; L CELL; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PROTEIN METABOLISM; PROTEIN SECRETION; REIMBURSEMENT; REVIEW; SIDE EFFECT; TREATMENT INDICATION; WEIGHT GAIN;

ADAMANTANE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NITRILES; PYRROLIDINES; TREATMENT OUTCOME;

EID: 63849133359     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Scheen AJ, Radermecker RP Philips JC, et al-Le traitement du diabète de type 2 : entre insulinosensibilisateurs et insulinosécrétagogues. Rev Med Liège, 2007, 62, (Numero Spécial), 40-46.
2. Scheen AJ, Paquot N.-Quelle nouvelle donne pour soigner les patients diabétiques de type 2 ? Médecine des MaladiesMé taboliques, 2009, 3, sous presse.
3. Golay A.-Metformin and body weight. Int J Obesity, 2008, 32, 61-72.
4. Scheen AJ, Paquot N, Lefébvre PJ.-United Kingdom Prospective Diabetes Study : 10 ans plus tard.... Rev Med Liège, 2008, 63, 624-629.
5. Nathan DM, Buse JB, Davidson MB, et al.-Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2009, 52, 17-30.
6. Consoli A, Gomis R, Halimi S, et al.-Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab, 2004, 30, 509-516.
7. Scheen AJ.-Pièges et conseils à propos de l'utilisation des antidiabétiques oraux conventionnels. Rev Med Liege, 2002, 57, 352-356.
8. De Flines J, Radermecker RP, Jandrain BJ, Scheen AJ.-Optimalisation du traitement pharmacologique chez un patient avec un diabète de type 2 nouvellement diagnostique. Rev Med Liege, 2009, 64, 103-109.
9. Radermecker RP.-Place des insulinosécrétagogues dansle traitement du diabète de type 2. Rev Med Liege, 2005, 60, 402-408.
10. Radermecker RP.-Le risque hypoglycémique chez le patient diabétique : implications thérapeutiques. Rev Med Liège, 2005, 60, 461-465.
11. Scheen AJ.-New therapeutic approaches in type 2 diabetes. Acta Clin Belg, 2008, 63, 402-407.
12. Scheen AJ.-Le glucagon-like peptide-1 (GLP-1), nou-velle cible dans le traitement du diabete de type 2. Rev MedLiege, 2007, 62, 216-219.
13. Drucker DJ, Nauck MA.-The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 2006, 368, 1696-1705.
14. Scheen AJ, Radermecker RP, Philips JC, Paquot N.-Les incré tinomimétiques et incrétinopotentiateurs dans le traitement du diabète de type 2. Rev Med Suisse, 2007, 3, 1884-1888.
15. Scheen AJ, Van Gaal LF.-Sitagliptine (Januvia®). Incré tinopotentiateur indiqué comme insulinosécrétagogue dans le traitement du diabète de type 2. Rev Med Liège, 2008, 63, 105-109.
16. Scheen AJ, Van Gaal LF.-Exénatide (Byetta®). Incrétinomimétique indiqué dans le traitement du diabète de type 2 après échec et en complément des antidiabétiques oraux. Rev Med Liège, 2008, 63, 158-165.
17. Garber AJ, Sharma MD.-Update : vildagliptin for the treatment of Type 2 diabetes. Expert Opin Investig Drugs, 2008, 17, 105-113.
18. Roxtall JD, Keam SJ.-Vildagliptin. A review of its use in the management of type 2 diabetes mellitus. Drugs, 2008, 68, 2387-2409.
19. Pratley RE, Schweizer A, Rosenstock J, et al.-Robust improvements in fasting and prandial measures of β-cell function with vildagliptin in drug-naive patients : analysis of pooled vildagliptin monotherapy database. Diab Obes Metab, 2008, 10, 931-938.
20. Lindsay JR, Duffy NA, McKillop AM, et al.-Inhibition of dipeptidylpeptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med, 2005, 22, 654-657.
21. Scheen AJ.-Interactions medicamenteuses : de la théorie à la pratique. Rev Med Liège, 2006, 61, 471-482.
22. 1c over 1 year in drug-naïve patients with Type 2 diabetes. Diabet Med, 2007, 24, 955-961.
23. Göke B, Hershon K, Kerr D, et al.-Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes : comparison with metformin. Horm Metab Res, 2008, 40, 892-895.
24. Rosenstock J, Baron MA, Dejager S, et al.-Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes. A 24-week, double-blind, randomized trial. Diabetes Care, 2007, 30, 217-223.
25. Halimi S, Schweizer A, Minic B, et al.-Combination treatment in the management of type 2 diabetes : focus on vildagliptin and metformin as a single tablet. Vasc Health Risk Manag, 2008, 4, 481-492.
26. Bosi E, Paolo Camisasca R, Collober C, et al.-Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care, 2007, 30, 890-895.
27. Ferrannini E, Fonseca V, Zinman B, et al.-Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controolled on metformin monotherapy. Diabetes Obes Metab, 2009, 11, 157-166.
28. Bolli G, Dotta F, Rochotte E, Cohen SE.-Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin : a 24-week, randomized, double-blind study. Diabetes Obes Metab, 2008, 10, 82-90.